Literature DB >> 6401562

Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems.

G R Venning.   

Abstract

The process of discovery for 18 important adverse drug reactions was analysed in terms of study designs and other features which determined whether published reports of suspected adverse reactions were convincing or provided valid evidence of causality. First alerts were almost always anecdotal reports. For earlier alerting during clinical trials event recording is needed, associated with dose-response data and the use of patients as their own controls.

Entities:  

Mesh:

Year:  1983        PMID: 6401562      PMCID: PMC1546762          DOI: 10.1136/bmj.286.6363.458

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-22

2.  Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29

3.  Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-15

4.  Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms.

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-23

5.  Record linkage for drug monitoring.

Authors:  D C Skegg; R Doll
Journal:  J Epidemiol Community Health       Date:  1981-03       Impact factor: 3.710

  5 in total
  21 in total

Review 1.  Case-population studies in pharmacoepidemiology.

Authors:  Dolors Capellà; Consuelo Pedrós; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Detection, verification, and quantification of adverse drug reactions.

Authors:  Bruno H Ch Stricker; Bruce M Psaty
Journal:  BMJ       Date:  2004-07-03

Review 3.  Pharmaco-epidemiological perspectives.

Authors:  U Bergman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

4.  Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors.

Authors:  C E Bucknall; J B Neilly; R Carter; R D Stevenson; P F Semple
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09

Review 5.  The art and science of risk management: a US research-based industry perspective.

Authors:  Janice K Bush; Wanju S Dai; Gretchen S Dieck; Linda S Hostelley; Thomas Hassall
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Signal detection: historical background.

Authors:  Toine C G Egberts
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Principles of signal detection in pharmacovigilance.

Authors:  R H Meyboom; A C Egberts; I R Edwards; Y A Hekster; F H de Koning; F W Gribnau
Journal:  Drug Saf       Date:  1997-06       Impact factor: 5.606

8.  Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals.

Authors:  T C Egberts; M Smulders; F H de Koning; R H Meyboom; H G Leufkens
Journal:  BMJ       Date:  1996-08-31

9.  Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis.

Authors:  Nicole Mittmann; Sandra R Knowles; Manuel Gomez; Joel S Fish; Robert Cartotto; Neil H Shear
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  A need to intensify drug surveillance in Germany.

Authors:  J F Kapp; R Zentgraf; A Widmer; E Schöpf
Journal:  Klin Wochenschr       Date:  1991-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.